Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ALDR
- CUSIP: N/A
- Web: www.alderbio.com
Capitalization:- Market Cap: $579.72 million
- Outstanding Shares: 50,410,000
Average Prices:- 50 Day Moving Avg: $14.84
- 200 Day Moving Avg: $19.49
- 52 Week Range: $10.05 - $36.48
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.87
- P/E Growth: -0.08
Sales & Book Value:- Annual Revenue: $112,999.00
- Price / Sales: 5,130.27
- Book Value: $5.71 per share
- Price / Book: 2.01
Profitability:- EBIDTA: ($223,700,000.00)
- Return on Equity: -57.41%
- Return on Assets: -54.28%
Debt:- Current Ratio: 10.47%
- Quick Ratio: 10.44%
Misc:- Average Volume: 1.66 million shs.
- Beta: 2.57
- Short Ratio: 12.44
Frequently Asked Questions for Alder BioPharmaceuticals (NASDAQ:ALDR)
What is Alder BioPharmaceuticals' stock symbol?
Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder BioPharmaceuticals' earnings last quarter?
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) released its quarterly earnings results on Thursday, April, 27th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.95) by $1.04. During the same period in the prior year, the company earned ($0.76) EPS. View Alder BioPharmaceuticals' Earnings History.
When will Alder BioPharmaceuticals make its next earnings announcement?
Where is Alder BioPharmaceuticals' stock going? Where will Alder BioPharmaceuticals' stock price be in 2017?
10 equities research analysts have issued 1-year price targets for Alder BioPharmaceuticals' shares. Their predictions range from $17.00 to $51.00. On average, they expect Alder BioPharmaceuticals' stock price to reach $39.40 in the next twelve months. View Analyst Ratings for Alder BioPharmaceuticals.
What are analysts saying about Alder BioPharmaceuticals stock?
Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (7/11/2017)
- 2. Needham & Company LLC analysts commented, "Results from the ongoing pivotal Phase 3 PROMISE-1 trial in patients with frequent episodic migraines (FEM) are expected this month. In the context of positive Phase 3 FEM results from all competitor CGRP antibody programs (AMGN, LLY, TEVA), we think PROMISE-1’s primary endpoint will generally be in-line with the competition. However, we expect differentiation with key secondary endpoints (≥75% reduction in migraine days over weeks 1-12 and weeks 1-4), which we think will be important for commercial success. We maintain our view that there is room for multiple players in the migraine prophylaxis market, and we believe Alder shares remain underappreciated even in a scenario where PROMISE-1 data are positive but undifferentiated. Alder’s current EV (~$550M) reflects treatment of just ~63k patients with eptinezumab in 2027 in our model, or <1% of our estimated 7.1M prevention therapy candidates."" (6/9/2017)
- 3. Aegis analysts commented, "We conducted an in-depth analysis of four late-stage monoclonal antibodies in development for migraine prevention – See table 1." (4/10/2017)
Who are some of Alder BioPharmaceuticals' key competitors?
Some companies that are related to Alder BioPharmaceuticals include Amarin Corporation PLC (AMRN), Clinigen Group PLC (CLIN), Xencor (XNCR), Insmed (INSM), Acorda Therapeutics (ACOR), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), NeuroDerm (NDRM), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), ZIOPHARM Oncology (ZIOP), Keryx Biopharmaceuticals (KERX), Achaogen (AKAO), Epizyme (EPZM), Aclaris Therapeutics (ACRS), Flexion Therapeutics (FLXN) and Retrophin (RTRX).
Who are Alder BioPharmaceuticals' key executives?
Alder BioPharmaceuticals' management team includes the folowing people:
- Stephen M. Dow, Independent Chairman of the Board
- Randall C. Schatzman Ph.D., President, Chief Executive Officer, Director
- Larry K. Benedict, Executive Vice President, Principal Accounting Officer
- James B. Bucher J.D., Senior Vice President, General Counsel
- Randal A. Hassler, Senior Vice President - Pharmaceutical Operations
- John A. Latham Ph.D., Chief Scientific Officer
- Mark James Litton Ph.D., Chief Business Officer, Treasurer and Secretary
- Elisabeth A. Sandoval, Chief Commercial Officer
- Jeffrey T.L. Smith M.D., Managing Director of Alder BioPharmaceuticals Limited
- Timothy M. Whitaker M.D., Chief Medical Officer
Who owns Alder BioPharmaceuticals stock?
Alder BioPharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fox Run Management L.L.C. (0.07%) and Daiwa SB Investments Ltd. (0.02%). Company insiders that own Alder BioPharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder BioPharmaceuticals.
Who sold Alder BioPharmaceuticals stock? Who is selling Alder BioPharmaceuticals stock?
Alder BioPharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd.. Company insiders that have sold Alder BioPharmaceuticals stock in the last year include Jeffrey T L Smith, John A Latham, Mark James Litton and Randall C Schatzman. View Insider Buying and Selling for Alder BioPharmaceuticals.
Who bought Alder BioPharmaceuticals stock? Who is buying Alder BioPharmaceuticals stock?
How do I buy Alder BioPharmaceuticals stock?
Shares of Alder BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alder BioPharmaceuticals' stock price today?
One share of Alder BioPharmaceuticals stock can currently be purchased for approximately $11.50.
MarketBeat Community Rating for Alder BioPharmaceuticals (NASDAQ ALDR)MarketBeat's community ratings are surveys of what our community members think about Alder BioPharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Alder BioPharmaceuticals (NASDAQ:ALDR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 9 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.90) |
| Consensus Price Target: | $39.40 (242.61% upside) |
Analysts' Ratings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | Needham & Company LLC | Set Price Target | Buy | $36.00 | Low |  |
| 7/5/2017 | Aegis | Reiterated Rating | Buy | $41.00 | Low | |
| 6/28/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $51.00 | High | |
| 6/28/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $47.00 | High | |
| 6/28/2017 | Credit Suisse Group | Downgrade | Outperform -> Neutral | $30.00 -> $17.00 | High | |
| 6/12/2017 | Leerink Swann | Reiterated Rating | Outperform | $32.00 | Medium | |
| 4/17/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $43.00 | Low | |
| 12/9/2016 | BMO Capital Markets | Reiterated Rating | Outperform | $42.00 | N/A | |
| 9/30/2016 | Brean Capital | Initiated Coverage | Buy | $45.00 | N/A | |
| 9/13/2016 | J P Morgan Chase & Co | Initiated Coverage | Overweight | $40.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)Earnings History by Quarter for Alder BioPharmaceuticals (NASDAQ ALDR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/24/2017 | | ($1.61) | | | | | N/A | |
| 4/27/2017 | Q1 2017 | ($0.95) | ($1.99) | | | View | N/A | |
| 2/23/2017 | Q4 2016 | ($0.90) | ($0.97) | | | View | N/A | |
| 10/27/2016 | Q3 | ($0.85) | ($0.70) | | | View | Listen | |
| 7/26/2016 | Q2 | ($0.75) | ($0.79) | $1.14 million | $0.11 million | View | Listen | |
| 4/28/2016 | Q1 | ($0.72) | ($0.76) | $0.14 million | | View | N/A | |
| 2/23/2016 | Q4 | ($0.65) | ($0.60) | | | View | Listen | |
| 11/5/2015 | Q315 | ($0.51) | ($0.62) | $0.23 million | | View | N/A | |
| 8/5/2015 | Q215 | ($0.40) | ($0.46) | $0.23 million | | View | N/A | |
| 5/7/2015 | Q115 | ($0.37) | ($0.40) | | | View | Listen | |
| 3/4/2015 | Q414 | ($0.18) | ($0.22) | $5.70 million | $6.40 million | View | N/A | |
| 11/3/2014 | Q314 | $0.05 | $0.88 | $14.84 million | $38.75 million | View | N/A | |
| 8/5/2014 | Q2 | ($0.22) | ($0.40) | $5.00 million | $4.70 million | View | N/A | |
| 6/20/2014 | Q1 | ($0.22) | ($5.38) | $4.60 million | $4.80 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)2017 EPS Consensus Estimate: ($3.83)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.98) | ($0.86) | ($0.92) |
| Q2 2017 | 2 | ($1.02) | ($0.85) | ($0.94) |
| Q3 2017 | 2 | ($1.02) | ($0.91) | ($0.97) |
| Q4 2017 | 2 | ($1.02) | ($0.99) | ($1.01) |
(Data provided by Zacks Investment Research)
Dividend History for Alder BioPharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Alder BioPharmaceuticals (NASDAQ:ALDR)Insider Ownership Percentage: 10.60%
Insider Trades by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/18/2017 | Stephen M Dow | Director | Buy | 25,000 | $10.00 | $250,000.00 | |
| 6/20/2017 | Jeffrey T L Smith | VP | Sell | 585 | $20.00 | $11,700.00 | |
| 1/18/2017 | Mark James Litton | Insider | Sell | 1,498 | $23.10 | $34,603.80 | |
| 1/9/2017 | Mark James Litton | Insider | Sell | 9,516 | $23.01 | $218,963.16 | |
| 12/1/2016 | Jeffrey T. L. Smith | VP | Sell | 3,000 | $22.78 | $68,340.00 | |
| 12/1/2016 | John A. Latham | Insider | Sell | 3,636 | $22.78 | $82,828.08 | |
| 11/7/2016 | Randall C Schatzman | CEO | Sell | 10,000 | $25.16 | $251,600.00 | |
| 10/17/2016 | Mark James Litton | Insider | Sell | 6,000 | $27.50 | $165,000.00 | |
| 10/3/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $31.14 | $93,420.00 | |
| 10/3/2016 | John A Latham | Insider | Sell | 10,000 | $31.32 | $313,200.00 | |
| 10/3/2016 | Randall C Schatzman | CEO | Sell | 8,181 | $31.15 | $254,838.15 | |
| 9/1/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $32.49 | $97,470.00 | |
| 9/1/2016 | Randall C Schatzman | Insider | Sell | 10,000 | $32.48 | $324,800.00 | |
| 8/15/2016 | Jeffrey T L Smith | VP | Sell | 3,000 | $31.17 | $93,510.00 | |
| 8/1/2016 | John A Latham | Insider | Sell | 10,000 | $31.19 | $311,900.00 | |
| 7/27/2016 | John A Latham | Insider | Sell | 10,000 | $30.14 | $301,400.00 | |
| 7/25/2016 | Randall C Schatzman | Insider | Sell | 10,000 | $28.08 | $280,800.00 | |
| 6/13/2016 | Mark James Litton | Insider | Sell | 6,000 | $28.94 | $173,640.00 | |
| 6/3/2016 | Jeffrey T L Smith | VP | Sell | 16,090 | $30.20 | $485,918.00 | |
| 6/1/2016 | John A Latham | Insider | Sell | 10,000 | $30.02 | $300,200.00 | |
| 5/31/2016 | Mark James Litton | Insider | Sell | 25,000 | $30.05 | $751,250.00 | |
| 5/27/2016 | John A Latham | Insider | Sell | 6,401 | $30.05 | $192,350.05 | |
| 5/24/2016 | Randall C Schatzman | CEO | Sell | 10,000 | $28.02 | $280,200.00 | |
| 4/18/2016 | Randall C Schatzman | CEO | Sell | 30,000 | $28.07 | $842,100.00 | |
| 1/4/2016 | Mark James Litton | insider | Sell | 25,000 | $31.40 | $785,000.00 | |
| 1/4/2016 | Randall C. Schatzman | CEO | Sell | 10,000 | $31.47 | $314,700.00 | |
| 12/1/2015 | Jeffrey T. L. Smith | VP | Sell | 4,272 | $37.24 | $159,089.28 | |
| 12/1/2015 | John A. Latham | insider | Sell | 4,550 | $37.24 | $169,442.00 | |
| 12/1/2015 | Randall C. Schatzman | CEO | Sell | 10,000 | $37.24 | $372,400.00 | |
| 11/30/2015 | Stephen M Dow | Director | Sell | 88 | $37.11 | $3,265.68 | |
| 11/2/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $33.67 | $131,313.00 | |
| 11/2/2015 | John A. Latham | insider | Sell | 4,545 | $33.69 | $153,121.05 | |
| 11/2/2015 | Randall C. Schatzman | CEO | Sell | 10,000 | $33.71 | $337,100.00 | |
| 10/1/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $32.25 | $125,775.00 | |
| 10/1/2015 | John A. Latham | insider | Sell | 4,545 | $32.26 | $146,621.70 | |
| 9/1/2015 | Jeffrey T. L. Smith | VP | Sell | 3,900 | $38.50 | $150,150.00 | |
| 9/1/2015 | John A. Latham | insider | Sell | 4,545 | $38.52 | $175,073.40 | |
| 8/31/2015 | Stephen M Dow | Director | Sell | 16,218 | $38.75 | $628,447.50 | |
| 6/12/2015 | Larry Benedict | VP | Sell | 25,454 | $47.46 | $1,208,046.84 | |
| 6/4/2015 | John A Latham | Insider | Sell | 25,000 | $44.18 | $1,104,500.00 | |
| 6/1/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $41.53 | $161,967.00 | |
| 6/1/2015 | John A Latham | Insider | Sell | 4,545 | $41.53 | $188,753.85 | |
| 5/22/2015 | Jeffrey T L Smith | VP | Sell | 61,818 | $38.86 | $2,402,247.48 | |
| 5/21/2015 | Stephen M Dow | Director | Sell | 20,000 | $65.69 | $1,313,800.00 | |
| 5/20/2015 | Stephen M Dow | Director | Sell | 8,462 | $40.39 | $341,780.18 | |
| 5/18/2015 | Clay B Siegall | Director | Sell | 38,181 | $37.62 | $1,436,369.22 | |
| 4/1/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $27.43 | $106,977.00 | |
| 4/1/2015 | John A Latham | Insider | Sell | 19,045 | $29.54 | $562,589.30 | |
| 3/30/2015 | John A Latham | Insider | Sell | 14,500 | $30.20 | $437,900.00 | |
| 1/27/2015 | Jeffrey T L Smith | VP | Sell | 3,900 | $28.01 | $109,239.00 | |
| 1/27/2015 | John A Latham | Insider | Sell | 15,045 | $28.33 | $426,224.85 | |
| 1/27/2015 | Randall C Schatzman | CEO | Sell | 100,000 | $28.42 | $2,842,000.00 | |
| 1/26/2015 | Jeffrey T L Smith | VP | Sell | 2,700 | $27.89 | $75,303.00 | |
| 1/26/2015 | Mark James Litton | Insider | Sell | 5,200 | $28.03 | $145,756.00 | |
| 1/26/2015 | Randall C Schatzman | CEO | Sell | 36,422 | $27.93 | $1,017,266.46 | |
| 11/24/2014 | Jeffrey T L Smith | VP | Sell | 29,090 | $16.08 | $467,767.20 | |
| 5/13/2014 | A/S Novo | Insider | Buy | 550,000 | $10.00 | $5,500,000.00 | |
| 5/13/2014 | Alan Bruce Montgomery | Director | Buy | 3,000 | $10.00 | $30,000.00 | |
| 5/13/2014 | West 8 Limited Partne Ventures | Major Shareholder | Buy | 250,000 | $10.00 | $2,500,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Alder BioPharmaceuticals (NASDAQ:ALDR)
Latest Headlines for Alder BioPharmaceuticals (NASDAQ:ALDR)
| Source: |
|
| Date | Headline |
|---|
 | Stephen M. Dow Buys 25,000 Shares of Alder BioPharmaceuticals, Inc. (ALDR) Stock
www.americanbankingnews.com - July 18 at 10:29 PM |
 | Alder BioPharmaceuticals nets $162 million to continue migraine drug development
www.bizjournals.com - July 18 at 10:14 PM |
 | Alder BioPharmaceuticals Announces Closing of Public Offering of Common Stock
finance.yahoo.com - July 18 at 5:11 PM |
 | Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta - TheStreet.com
www.thestreet.com - July 17 at 4:02 PM |
| Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - July 17 at 8:20 AM |
| Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 14 at 5:05 PM |
 | Alder BioPharma (ALDR) Prices 15M Share Offering at $10/Sh
www.streetinsider.com - July 14 at 2:32 AM |
 | Alder Biopharmaceuticals Inc. (ALDR) Fell To A New Low After Offering
www.rttnews.com - July 14 at 2:32 AM |
| Alder BioPharmaceuticals, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - July 14 at 2:32 AM |
| Cramer: Mea culpa! This stock's action is why I say small-cap biotechs are only for speculation
finance.yahoo.com - July 14 at 2:32 AM |
 | Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back - Motley Fool
www.fool.com - July 13 at 9:29 PM |
| Why I say small-cap biotechs are only for speculation
finance.yahoo.com - July 13 at 9:29 PM |
| Alder BioPharmaceuticals: Cramer's Top Takeaways
finance.yahoo.com - July 13 at 9:29 PM |
 | Pre-Market Most Active for Jul 13, 2017 : YNDX, FOLD, SNAP, MT, ALDR, ARNA, TEF, QAT, DAL, TGT, QQQ, TEVA - Nasdaq
www.nasdaq.com - July 13 at 4:26 PM |
| BUZZ-US STOCKS ON THE MOVE- Yandex, US Retailers, Navigator, Alder BioPharma - Nasdaq
www.nasdaq.com - July 13 at 4:25 PM |
| Today's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc.
finance.yahoo.com - July 13 at 4:25 PM |
| Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back
finance.yahoo.com - July 13 at 4:25 PM |
| Why Alder Biopharmaceuticals Inc Is Sinking Today - Motley Fool
www.fool.com - July 13 at 2:12 AM |
 | Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - July 12 at 9:12 PM |
| Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock
finance.yahoo.com - July 12 at 9:11 PM |
 | Mid-Morning Market Update: Markets Open Higher; Fastenal Earnings Top Views - Benzinga
www.benzinga.com - July 12 at 4:10 PM |
| Mid-Afternoon Market Update: NASDAQ Up Over 1%; MSC Industrial Shares Plummet - Nasdaq
www.nasdaq.com - July 12 at 4:10 PM |
| BUZZ-US STOCKS ON THE MOVE-Ocular Therapeutix, NRG Energy, Alder BioPharma, Cara - Nasdaq
www.nasdaq.com - July 12 at 4:10 PM |
| Wednesday’s Biotech Movers: Ibio Inc (IBIO) Rallies, Ocular Therapeutix Inc (OCUL) Tumbles, Alder Biopharmaceuticals Inc (ALDR) Dives
finance.yahoo.com - July 12 at 4:10 PM |
| Alder Biopharmaceuticals Inc. (ALDR) Is Down After Offering Announcement
www.rttnews.com - July 12 at 2:57 AM |
| Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM |
| Alder BioPharmaceuticals, Inc. Announces Commencement of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - July 11 at 4:55 PM |
| Alder BioPharmaceuticals, Inc. Announces Commencement of Public Offering of Common Stock
finance.yahoo.com - July 11 at 4:55 PM |
| Aegis Reiterates Buy Rating for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
www.americanbankingnews.com - July 5 at 9:54 AM |
| FY2018 EPS Estimates for Alder BioPharmaceuticals, Inc. Cut by Leerink Swann (ALDR)
www.americanbankingnews.com - June 30 at 11:53 AM |
| Alder BioPharmaceuticals, Inc. (ALDR) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - June 29 at 11:44 PM |
| Alder Biopharma Plummets After Results Of Eptinezumab 1 Phase Trial - Benzinga
www.benzinga.com - June 28 at 8:56 PM |
 | Alder's Headache Worsens - Seeking Alpha
seekingalpha.com - June 28 at 8:56 PM |
 | Alder's Shares Dip Despite Positive Migraine Trial Results
www.zacks.com - June 28 at 3:54 PM |
| Alder Biopharmaceuticals Inc Sell-Off A Buying Opportunity? Needham Weighs In
finance.yahoo.com - June 28 at 3:54 PM |
| Alder's Shares Dip Despite Positive Migraine Trial Results
finance.yahoo.com - June 28 at 3:54 PM |
| Wells Fargo & Company Reiterates "Outperform" Rating for Alder BioPharmaceuticals, Inc. (ALDR)
www.americanbankingnews.com - June 28 at 1:50 PM |
| Alder BioPharmaceuticals, Inc. (ALDR) Earns Buy Rating from Needham & Company LLC
www.americanbankingnews.com - June 28 at 1:50 PM |
| Alder BioPharmaceuticals' (ALDR) Overweight Rating Reaffirmed at Piper Jaffray Companies
www.americanbankingnews.com - June 28 at 12:40 PM |
| Alder BioPharmaceuticals, Inc. (ALDR) Rating Lowered to Neutral at Credit Suisse Group
www.americanbankingnews.com - June 28 at 8:16 AM |
| Mid-Day Market Update: Crude Oil Up Over 2%; Xenon Pharmaceuticals Shares Slide - Benzinga
www.benzinga.com - June 27 at 8:34 PM |
| Alder Shares Plummet Almost 25% Despite Positive Data; Aralez Pops on Patent Victory: Biotech Movers - TheStreet.com
www.thestreet.com - June 27 at 8:34 PM |
| Implied Volatility Surging for Alder Biopharmaceuticals (ALDR) Stock Options - Nasdaq
www.nasdaq.com - June 27 at 8:34 PM |
 | Alder BioPharma stock drops nearly 20% as investors shrug off positive migraine drug results - MarketWatch
www.marketwatch.com - June 27 at 8:34 PM |
| Alder’s flagship migraine drug trial posts strong results — and so does the placebo
finance.yahoo.com - June 27 at 8:34 PM |
| Piper Jaffray Defends Alder Despite Stock Slump, Looks To What's Next In Migraine Management
www.benzinga.com - June 27 at 3:32 PM |
| Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine
finance.yahoo.com - June 27 at 3:32 PM |
| Alder's migraine drug meets main goal in late-stage study
finance.yahoo.com - June 27 at 3:32 PM |
| Implied Volatility Surging for Alder Biopharmaceuticals (ALDR) Stock Options
finance.yahoo.com - June 27 at 3:32 PM |
| Alder BioPharma stock drops nearly 20% as investors shrug off positive migraine drug results
finance.yahoo.com - June 27 at 3:32 PM |
Alder BioPharmaceuticals (ALDR) Chart for Saturday, July, 22, 2017
